Abstract: A cooling and/or heating system for cooling and/or heating plant roots includes at least one heat transfer element to be disposed in a growth base close to plant roots and a 3D textile through which a fluid can flow and which comprises at least one fluid inlet for admitting the fluid and at least one fluid outlet for discharging the fluid. A device with such a cooling and/or heating system and a growth base for plants, and a method for cooling and/or heating plant roots, where fluid of a determined temperature flows through the at least one heat transfer element for the purpose of cooling and/or heating plant roots.

Abstract: The present invention pertains to a method for keeping an immunogenic composition available for administration to an animal, wherein said composition comprises an antigen and an emulsion which is a single emulsion at a first temperature below a body temperature of the animal and which emulsion reverses at a second temperature between the first temperature and the body temperature, said method comprising providing the composition, freezing the composition, and storing the frozen composition until it is needed for administration to the animal. The invention also pertains to a method for testing an immunogenic composition, and an immunogenic composition, optionally in combination with specific instructions for storing the composition.

Abstract: The present invention pertains to a method for keeping an immunogenic composition available for administration to an animal, wherein said composition comprises an antigen and an emulsion which is a single emulsion at a first temperature below a body temperature of the animal and which emulsion reverses at a second temperature between the first temperature and the body temperature, said method comprising providing the composition, freezing the composition, and storing the frozen composition until it is needed for administration to the animal. The invention also pertains to a method for testing an immunogenic composition, and an immunogenic composition, optionally in combination with specific instructions for storing the composition.

Abstract: Foot and mouth disease (FMD) viruses which are able to grow on BHK-21 cells in suspension are described herein. The new viruses are recombinant chimeric viruses formed by replacing the outer capsid coding region of a first FMDV strain, which has previously been shown to be an effective vaccine strain, with the outer capsid coding region of a second FMDV strain. The outer capsid coding region of the second FMDV strain is also modified to introduce a heparan sulphate proteoglycan (HSPG) binding site. The chimeric viruses are then used as seed viruses in the production of inactivated vaccine antigens which have been tailored for specific outbreak situations or locality. The invention also relates to the product of expression of the chimeric FMD viruses and to uses therefor, such as to form antigenic, immunological or vaccine compositions for prevention of FMD.

Abstract: The present invention relates to a needle-less injector having a housing comprising: a chamber defined within said injector for containing liquid to be injected; a liquid outlet for said chamber positioned at the front end of the injector; a dispensing member in contact with the liquid in said chamber and movable in a first direction to reduce the volume of said chamber to cause the liquid contained therein to be expelled through said liquid outlet; an impacting member arranged to strike said dispensing member to cause movement thereof in said first direction; drive means connected to the impacting member for actuating said injector, or permitting actuation thereof, in response to the application of a selected amount of axial pressure, characterized in that the housing is essentially unitary and the chamber, the liquid outlet and the drive means are immobile with respect to the housing, and that the injector comprises a pressure sensor in order to sense the axial pressure, which pressure sensor is connected t

Abstract: The present invention is directed to the identification of the causative agent of Porcine Reproductive Respiratory Syndrome virus and vaccines derived therefrom. The present invention is also directed to viral antigens produced by tissue culture cells infected with this virus, and the use of such antigens in diagnostics.

Abstract: The present invention relates to a vaccine against a virus associated with antibody-dependent-enhancement of viral infectivity. Such a vaccine comprises a herpesvirus vector which is able to spread from cell-to-cell and which does produce non-infectious progeny virions having a gene encoding an antigen of said virus inserted into the herpesvirus genome.

Abstract: The present invention is concerned with European strains of the Porcine Reproductive Respiratory Syndrome (PRRS) virus, which are attenuated, and show a characteristic reaction pattern with two monoclonal antibodies against wild-type PRRSV.The invention also relates to vaccines for the protection of pigs against PRRS, to monoclonal antibodies reactive with PRRS virus and monoclonal antibodies specifically non-reactive with the attenuated strains.

Abstract: The present invention is concerned with a genetically modified live herpesvirus vaccine of which the live herpesviruses are not shed into the environment by a vaccinated animal. This can he achieved by deleting a gene encoding a gD homolog, such as gp50 of pseudorabies virus, and propagating this deletion mutant in a cell line expressing the gene product. The reduced shedding characteristic of such a vaccine is particularly advantageous in a vector vaccine. The present invention also concerns a quadruple mutant pseudorabies virus vaccine, and a live cell bound vaccine containing gp50 mutant pseudorabies virus and cells which do not complement the mutation.

Abstract: The present invention concerns novel immunogens. These immunogens comprise novel compounds which consist of an antigen or antigenic determinant couple dot an amphiphilic adjuvant molecule and optionally also free amphiphilic adjuvant molecules. An advantageous features of these novel immunogens is the presence of both an excellent immunogen activity as well as a pronounced adjuvant activity in a single complex.

Abstract: Vaccines containing both E.coli and herpes virus were found not to provide adequate protection against subsequent herpes virus infections. The present invention is concerned with a E.coli herpes virus combined vaccine which provides protection against both types of pathogen.